GrassMATAMPL: Completed Phase IIb enrollment

Allergy Therapeutics completed enrollment of 250 patients with seasonal allergic rhinoconjunctivitis exposed to grass pollen in the double-blind, placebo-controlled, U.S. Phase II G204 trial evaluatin...